Thus, CPT11 resistance might be related to the SCC population and ABCG2 expression, whereas CVV showed dose-dependent responses regardless of the SCC population, suggesting that our CVV might overcome drug resistance originating from the stem cell-like colon cancer cell population. This evidence concerns the gene ABCG2 and colonic neoplasm.